Dr. Reddy's Laboratories Limited has informed the Exchange about Investor Presentation
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's reported Q1 FY26 consolidated revenues of ₹8,545 Cr, up 11% year-on-year but flat sequentially. EBITDA came in at ₹2,278 Cr with margins improving to 26.7% (up from 24.7% QoQ), while PAT grew 2% YoY to ₹1,418 Cr. The company maintains a strong net cash surplus of ₹2,922 Cr and an annualised RoCE of around 22%. Segment-wise, Europe surged 142% YoY on NRT portfolio contribution, India grew 11%, Emerging Markets rose 18%, while North America grew 11% despite price erosion in products like Lenalidomide. The PSAI segment saw margin compression to 13% from 23% a year ago. Three USFDA inspections resulted in Form 483 observations across sites, with a VAI classification for Middleburgh.
The results show healthy topline growth and margin expansion quarter-on-quarter, supported by strong India and Emerging Markets performance, though USFDA observations and PSAI margin pressure remain watchpoints. The robust net cash position and improving RoCE signal financial strength, likely positive for shareholder sentiment.